secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0000950170-25-037600
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA appoints Dr. Craig Tendler (ex-J&J oncology VP) to Board, effective March 10, 2025
--------------------------------------------------------------------------------

- Dr. Tendler oversaw 30 major oncology drug approvals at J&J, including DARZALEX, ZYTIGA, and BALVERSA.
- Received option to purchase 151,883 shares of HURA common stock at closing price on grant date.
- TuHURA plans to begin Phase 3 trial of IFx-2.0 in Q2 2025; Tendler's experience expected to aid regulatory strategy.
- Board expanded from five to six members with this appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017025037600/0000950170-25-037600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017025037600/hura-20250307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-037600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer